Acute Coronary Syndromes: From the Emergency Department to the Coronary Care Unit to the Office

Credit Area      

Release Date: Jul 16, 2012          Expiration Date: Jul 16, 2013



This program has an associated Grand Rounds; Click Here for information.

Program Description


This program explores the state-of-the-art treatment of patients with acute coronary syndromes (ACS), and analyzes the latest clinical trial results on new treatment options, while identifying particular patient characteristics that favor one treatment option over another. Participants will learn to recognize early symptom presentation, accurately diagnose ACS in their patients, and be able to make informed decisions when selecting the most appropriate treatment options in order to provide optimum management of ACS patients.


Faculty


DEEPAK L. BHATT, MD, MPH, FACC, FAHA, FSCAI
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular Program
Brigham and Women’s Hospital and
VA Boston Healthcare System
Associate Professor of Medicine, Harvard Medical School
Senior Investigator, TIMI Study Group
Boston, MA
Read Biography

CHARLES V. POLLACK JR., MA, MD, FACEP, FAAEM, FAHA
Professor and Chairman
Department of Emergency Medicine
Pennsylvania Hospital
University of Pennsylvania
Philadelphia, PA
Read Biography


Target Audience


This program is intended for preventive cardiologists, interventional cardiologists, emergency room physicians, internal medicine physicians, cath lab personnel, and other health care professionals involved in the acute treatment of ACS patients.


Educational Objectives


This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Adopt ischemic risk assessment stratification strategies to choose the best course of action to manage patients with acute chest pain syndrome
  • Assess and stratify bleeding risk after antiplatelet treatment is initiated
  • Make treatment choices based on an understanding of the different mechanisms of action among antithrombotic agents, and on pertinent clinical trial results
  • Analyze pharmacologic and clinical trial results of newer antithrombotic agents to determine how best to match treatment options with patients to achieve optimal clinical outcome

Accreditation


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe Corporation. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.


Designation Statement


The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit, the post-test, or evaluation, please email contact@potomacme.org


Disclosure Statement


The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI: Research: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, The Medicines Company, Medtronic, Sanofi-Aventis

Charles V. Pollack Jr., MA, MD, FACEP, FAAEM, FAHA: Consultant: Forest Laboratories, Merck

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Barry Watkins, PhD; Bradley Pine; Blair St. Amand; Jay Katz; Dana Simpler, MD: Nothing to Disclose


FDA Disclosure


The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


System Requirements


In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.

Instructions for Participants and Obtaining CME Credit


There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test.


Jointly Sponsored By


Potomac Center for Medical Education and Rockpointe

Supported By


Supported by an independent educational grant from
Daiichi Sankyo, Inc. and Lilly USA, LLC


By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.